Latest Press Releases
BioPorto submits answers to the FDA regarding The NGAL Test™ for risk assessment for AKI in pediatric patients
Response supplements the BioPorto application for pediatric use of The NGAL Test™ for risk assessment of acute kidney injury (AKI).
October 17, 2019
BioPorto Submits Pediatric Application to FDA for The NGAL Test™ Under Breakthrough Designation
First test focused on risk assessment of Acute Kidney Injury in pediatric patients.
May 15, 2019
BioPorto Appoints New President of BioPorto Diagnostics, Inc.
Company Plans to Bring Novel Kidney Diagnostic to US Market
April 15, 2019
BioPorto A/S - Annual General Meeting
BioPorto A/S held its Annual General Meeting where the shareholders took note of the report on the Company’s activities and adopted the 2018 Annual Report.
March 18, 2019